Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 701–800 of 982
Taylor, A. S., & Skala, S. L. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.04.043 · Cited by 4
The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies
Schmidt, L. S., Srinivasan, R., & Linehan, W. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_1 · Cited by 4
Foo, T., Nama, V., Attygalle, A. D., Williams, J., Heelan, K., Butler, S., & McVeigh, T. P. (2021) · Familial Cancer · doi:10.1007/s10689-021-00272-y · Cited by 4
Shveiky, D., Rojansky, N., Bassat, H. B., Ben‐Meir, A., Klein, B., & Shushan, A. (2009) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2009.06.012 · Cited by 4
Imagerie moléculaire nucléaire des paragangliomes
Taïeb, D., Tessonnier, L., & MUNDLER, O. (2010) · Médecine Nucléaire · doi:10.1016/j.mednuc.2010.06.009 · Cited by 4
The effects of phenolic microbial metabolites on the activities of mitochondrial enzymes
Fedotcheva, N. I., Litvinova, E. G., Osipov, A. A., Olenin, A. Y., Moroz, V. V., & Nv, B. (2015) · BIOPHYSICS · doi:10.1134/s0006350915060068 · Cited by 4
Pathologies liées aux déficits du cycle de Krebs
Bénit, P., Bortoli, S., Chrétien, D., Rak, M., & Rustin, P. (2018) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(18)30120-5 · Cited by 4
“REVUE FRANCOPHONE DES LABORATOIRES • N° 501 • AVRIL 2018 pour les cancers associés [5,20].”
BackgroundSelf-citationGroignet, L., Dellemme, D., Duez, Q., Fizazi, A., Colet, J.-M., Brocorens, P., Surin, M., Gerbaux, P., & Winter, J. D. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00259 · Cited by 3
Xian, J., Pan, X., Kang, Y., Zheng, L., Yin, X., Zhang, M., Wei, Y., Tan, J., Zhang, M., Nie, L., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03195-y · Cited by 3
Łoń, I., Kunikowska, J., Jędrusik, P., Góra, J., Toutounchi, S., Placha, G., & Gaciong, Z. A. (2021) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2021.01047 · Cited by 3
“Molecular data showed that mutations in the genes coding for SDH subunits result in accumulation of succinate and inhibition of HIF-1 hydroxylases leading to stabilization of HIF1 (28,29).”
BackgroundDai, K., Jiang, W., Chen, S., Luo, S., Ding, S., & Wang, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.932996 · Cited by 3
“HLRCC-associated RCC is an autosomal dominant genetic RCC caused by germline mutations of the FH gene which is an enzyme that catalyzes the transformation of fumaric acid into malic acid in the Krebs cycle (6, 7).”
BackgroundTumor metabolism in pheochromocytomas: clinical and therapeutic implications
Jeeyavudeen, M. S., Mathiyalagan, N., Fernandez, C. J., & Pappachan, J. M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00222 · Cited by 3
Rodríguez, S., Rodríguez-Jaime, M. F., & León-Prieto, C. (2024) · Critical Reviews in Physical and Rehabilitation Medicine · doi:10.1615/critrevphysrehabilmed.2024052624 · Cited by 3
Cytoprotective Action of Sodium Fumarate in an in vitro Model of Hypoxia Using Sodium Dithionite
Vinokurov, A. Y., Popov, S. V., Belyakov, D. Y., Popov, D. Y., Nikulin, A. S., Zakrzhevskaya, V. D., Guseinov, R. G., Сивак, К. В., Dunaev, A., Potapova, E. V., et al. (2025) · Современные технологии в медицине · doi:10.17691/stm2025.17.1.09 · Cited by 3
Presurgical Succinate MetAstatic Risk Tool (P-SMART) in Paragangliomas
Rapizzi, E., Zanatta, L., Santi, A., Staderini, F., Galeotti, N., Ercolino, T., Amore, F., Sparano, C., Maggi, M., & Canu, L. (2025) · Endocrine Pathology · doi:10.1007/s12022-025-09878-9 · Cited by 3
“Accumulated succinate acts as an oncometabolite by inhibiting HIF-1α prolyl hydroxylases (PHD) and α-ketoglutarate-dependent dioxygenases, including histone and DNA demethylases [20, 21].”
Molecular Basis of Response to Hypoxia
Krishnan, A., & Ansari, H. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-7652-2_2 · Cited by 3
The expression of succinate dehydrogenase in breast phyllodes tumor.
Choi, J., Kim, D. H., Jung, W., & Koo, J. S. (2014) · PubMed · doi:10.14670/hh-29.1343 · Cited by 3
Uterine Mesenchymal Tumors: Hereditary Aspects
Joehlin-Price, A. S., & Garg, K. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000175 · Cited by 3
Glutamine-dependent effects of nitric oxide on cancer cells subjected to hypoxia-reoxygenation
Xing, D., Benavides, G. A., Johnson, M. S., Tian, R., Barnes, S., & Darley-Usmar, V. M. (2022) · Nitric Oxide · doi:10.1016/j.niox.2022.11.003 · Cited by 3
Genetics and Tumor Microenvironment of Renal Cell Carcinoma
Khaleel, S. S., Ricketts, C. J., Linehan, W. M., Ball, M. W., Manley, B. J., Turajlic, S., Brugarolas, J., & Hakimi, A. A. (2022) · Société Internationale d’Urologie Journal · doi:10.48083/blpv3411 · Cited by 3
Mitochondria as Targets for Cancer Therapy
Ralph, S. J., & Neužil, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_12 · Cited by 3
Metabolic Remodeling in Bioenergetic Disorders and Cancer
Obre, É., & Rossignol, R. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1824-5_1 · Cited by 3
Sexual dimorphism of STGC3 tumor suppressor function in nasopharyngeal carcinoma CNE2 cells
Qiu, Q., Hu, B., Chen, Z. C., & He, X.-P. (2012) · Genetics and Molecular Research · doi:10.4238/2012.october.9.9 · Cited by 3
Lack of Major Genome-Wide DNA Methylation Changes in Succinate-Treated Human Epithelial Cells
Cui, W., Huang, Z., & Pfeifer, G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105663 · Cited by 3
Koeman, J. M., Russell, R. C., Tan, M., Petillo, D., Westphal, M., Koelzer, K., Metcalf, J. L., Zhang, Z., Matsuda, D., Dykema, K. J., et al. (2008) · PLoS Genetics · doi:10.1371/annotation/7f57058f-cc02-45a6-bfab-a835619e3916 · Cited by 3
A novel lineage-tracing tool reveals that hypoxic tumor cells drive tumor relapse after radiotherapy
Menegakis, A., Vennin, C., Ient, J., Groot, A. J., Krenning, L., Klompmaker, R., Friskes, A., Ilić, M., Yaromina, A., Harkes, R., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110592 · Cited by 2
Zhou, Y., Zhang, W., Cui, Y., Li, T., Li, Z., & Tong, A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf575 · Cited by 2
Wang, R., & Yan, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1671115 · Cited by 2
The Role of the Surgical Pathologist in the Recognition of Hereditary SDH-Deficient Tumor Syndromes
Juhlin, C. C., & Mete, Ö. (2026) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000541 · Cited by 2
Jiménez, C., Waguespack, S. G., Kaplan, J., Habra, M. A., & Varghese, J. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag324 · Cited by 2
Multiple Cutaneous and Uterine Leiomyomatosis
Makino, T. (2013) · InTech eBooks · doi:10.5772/53601 · Cited by 2
“Fumarate, the substrate of FH, is shown to accumulate into the cytoplasm of cells and cause stabilization of HIF1 by inhibiting α-ketoglutarate (α-KG) dependent dioxygenase in MUCL/HLRCC tumors because of an FH defect [41-44].”
MECHANISMS OF AT101 ((-)-GOSSYPOL) INDUCED CYTOTOXICITY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Kaza, N. (2014) · Cited by 2
Mitochondria Remodeling in Cancer
Dornfeld, K. J., & Skildum, A. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-73344-9_9 · Cited by 2
Gupta, S., & Erickson, L. A. (2023) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2026.06.010 · Cited by 2
A big picture of the mitochondria-mediated signals: From mitochondria to organism
Acar, N. V., & Özgül, R. K. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.08.032 · Cited by 2
Kurtz, A., Wenger, R. H., & Eckardt, K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-381462-3.00092-6 · Cited by 2
Saavedra, F., Boyarchuk, E., Alvarez, F., Almouzni, G., & Loyola, A. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_23 · Cited by 2
Protein succination as a potential surrogate biomarker of airway obstruction. The ilervas project
González, J., Gràcia‐Lavedan, E., Pamplona, R., Fernández, E., Lecube, A., de-Torres, J. P., Barbé, F., Torres, G., Benabdelhak, I., Bermúdez-López, M., et al. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106124 · Cited by 2
Cancer Hypoxia and the Tumour Microenvironment as Effectors of Cancer Metabolism
Armitage, E. G., Kotze, H. L., & Williams, K. J. (2014) · SpringerBriefs in systems biology · doi:10.1007/978-1-4939-0615-4_2 · Cited by 2
“Mutations in succinate dehydrogenase (SDH) and fumarate hydratase (FH) lead to increased levels of succinate and fumarate, respectively, which inhibit activity of the HIF–PHD enzymes, resulting in stabilisation in “aerobic” conditions (Isaacs et al. 2005; Pollard et al. 2005; Selak et al. 2005).”
BackgroundFrom Immunotherapy of Cancer to the Discovery of Kidney Cancer Genes: A Personal History
Zbar, B. (2013) · Colloquium Series on The Genetic Basis of Human Disease · doi:10.4199/c00074ed1v01y201303gbd003 · Cited by 2
Park, H. (2008) · Toxicological Research · doi:10.5487/tr.2008.24.2.101 · Cited by 2
“Consequently, HIF is activated in most of cancers and contributes to survival and progression of cancers by triggering angiogenesis, glycolysis, H+ export and metastasis (Esteban and Maxwell, 2005; Esteban et al., 2006; Isaacs et al., 2005; Koike et al., 2004; Pouysségur et al., 2006).”
BackgroundGenetic Diagnosis of Pheochromocytoma
Takekoshi, K., Isobe, K., & Kawakami, Y. (2008) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.97.2558 · Cited by 2
Experimental and Study Design Considerations for Uncovering Oncometabolites
Haznadar, M., & Mathé, E. A. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6539-7_4 · Cited by 2
Weihe, E. (2009) · State and University Library Bremen · Cited by 2
Síndromes de cáncer renal familiares y hereditarios
Coleman, J. (2008) · Clínicas urológicas de Norteamérica · Cited by 2
Cutaneous manifestations of hereditary syndromes
Heymann, W. R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1045 · Cited by 2
Angiogenesis, Arteriogenesis, and Mitochondrial Dysfunction
McMurtry, M. S. (2013) · Springer eBooks · doi:10.1007/978-1-4614-5930-9_15 · Cited by 2
Renal cell carcinoma: molecular pathways and targeted therapy
Gnjidić, M., & Fucak, I. K. (2014) · Periodicum Biologorum · Cited by 2
Tena, I., Ponce, J. L., Tajahuerce, M., Vercher-Conejero, J. L., Cifrián, M., Wolf, K. I., Miret, M., Olmo-García, M. I. D., Reboll, R., Conde-Moreno, A. J., et al. (2017) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2017.12.001 · Cited by 2
Alhammadi, L., Abdulla, M. A., Ahli, N., Dhahouri, N. A., Aidaros, A. A., Al-Jasmi, F., & Al-Dirbashi, O. Y. (2019) · Journal of Biochemical and Clinical Genetics · doi:10.24911/jbcgenetics/183-1563341940 · Cited by 2
“Mutations in specific TCA cycle genes such as those encoding fumarate hydratase and succinate dehydrogenase have been linked to certain types of tumors (4,5).”
BackgroundParaganglioma and Pheochromocytoma
Iacobone, M., & Torresan, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62241-1_15 · Cited by 2
Metabolic reprogramming and immunity in cancer
Chen, Y., & Li, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00006-5 · Cited by 2
Oncometabolites, epigenetic marks, and DNA repair
Dow, J., & Glazer, P. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91081-1.00008-x · Cited by 2
Mitochondrial-to-Nuclear Communications in Cancer
Dakubo, G. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-11416-8_4 · Cited by 2
The role of ascorbate in the regulation of HIF-1 in cancer cells
Kuiper, C. (2013) · Otago University Research Archive (University of Otago) · Cited by 2
MOLECULAR AND CLINICAL CHARACTERISTICS OF TRICARBOXYLIC ACID CYCLE-ASSOCIATED TUMORS
Lehtonen, H. J. (2008) · Helda - University of Helsinki Institutional Repository · Cited by 2
Hynninen, P. (2014) · Tampere University Institutional Repository (Tampere University) · Cited by 2
The Role Of Fumarase (FH) In Tumorigenesis
Lehtonen, R. (2006) · Helda - University of Helsinki Institutional Repository · Cited by 2
Mitochondrial modulators of hypoxia-related pathways in tumours
Snell, C. E. (2013) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-aememajj6 · Cited by 2
Investigating the role of alanine aminotransferase 2 in breast cancer
Mitra, D. (2018) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00024147 · Cited by 2
“Both these metabolites have been implicated in epigenetic modifications leading to DNA and histone hypermethylation and activation of hypoxic signaling(Gimenez-Roqueplo et al., 2002; Hoekstra et al., 2015; Isaacs et al., 2005; Killian et al., 2013; Letouzé et al., 2013; Pollard et al., 2005).”
BackgroundMetabolomics and Metallomics Analyses of Renal Cell Carcinoma and Prostate Cancer
Falegan, O. S. (2019) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/37098 · Cited by 2
Deficiência das enzimas do ciclo de Krebs
Silva, J. H. (2016) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
AMPK, signalisation hypoxique et métabolisme tumoral
Pelletier, J. (2014) · theses.fr (ABES) · doi:10.70675/e8022243z3bc3z4867zb254zc427ebc7f825 · Cited by 2
“Ce dernier rétro‐inhibe alors les PHDs et stabilise HIF en normoxie, créant un état de « pseudohypoxie » (Pollard et al., 2005; Sudarshan et al., 2009).”
The 3PAs syndrome and succinate dehydrogenase deficiency in pituitary tumors
Xekouki, P., Daraki, V. N., Betsi, G., Chrysoulaki, M., Sfakiotaki, M., Mytilinaiou, M. G., & Stratakis, C. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814537-1.00001-4 · Cited by 1
Tkachuk, E. A., Astakhova, T. A., Рычкова, Л. В., & Витальевна, Б. О. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-414 · Cited by 1
Neurodegenerative Diseases and Succinate Dehydrogenase: A Therapeutics Avenue for Treatment
Viswalingam, V., & Kumar, D. (2025) · Springer eBooks · doi:10.1007/978-981-96-6831-1_9 · Cited by 1
Pro-tumoural effects of vitamin C supplementation in a zebrafish model for SDHB -associated PPGL
Miltenburg, J. B., Strijker, N., Gorissen, M., ten Seldam, F., van Woerkom, L., Zethof, J., Küsters, B., Peitzsch, M., Timmers, H. J. L. M., & Dona, M. (2025) · Endocrine Related Cancer · doi:10.1530/erc-25-0370 · Cited by 1
Goncalves, P. D., & Sadow, P. M. (2026) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000528 · Cited by 1
Saeed, S., Khan, S., Noor, A., Zerr, I., & Zafar, S. (2026) · Molecular Informatics · doi:10.1002/minf.70024 · Cited by 1
“Just as fumaric aciduria causes severe neurological impairment, developmental delay, and seizures, elevated fumarate, which is also a harmful oncome-tabolite, may exacerbate neuronal vulnerability by impairing TCA cycle flux and mitochondrial ATP production in rpAD [53, 54].”
Wang, Y., Xiong, Y., Liu, S., Bao, L., Qiu, X., Korboukh, I., Song, X., Tcheuyap, V. T., Wu, S., Chen, M., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102630 · Cited by 1
“…mutations in prolyl hydroxylase domain 2, fumarate hydratase, and succinate dehydrogenase also cause constitutive activation of HIF in cancer cells, 39,40 suggesting that dDNMT and TRAIL combo may have a broad therapeutic application in these human cancers with constitutive activation of HIF.”
Zhao, X.-P., Mai, C.-T., Zhao, Y., Zhou, X.-Y., Lai, N.-H., Zhang, X.-J., & Fan, X. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189590 · Cited by 1
Sánchez‐Castillo, A., Lommen, J. G. E., Consten, D., Savelkouls, K. G. M., Barbeau, L. M. O., Rouschop, K. M. A., Vooijs, M., & Kampen, K. R. (2026) · Cancer & Metabolism · doi:10.1186/s40170-026-00433-6 · Cited by 1
“Furthermore, germline mutations in the genes encoding succinate dehydrogenase and fumarate hydratase result in increased levels of the TCA cycle metabolites fumarate and succinate that inhibit PHD activity [21, 93].”
Groignet, L., Robert, T., Duez, Q., Claessens, J., Brocorens, P., Gerbaux, P., & Winter, J. D. (2026) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.6c00118 · Cited by 1
Metabolic–epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment
Noh, J., Lee, J., You, C., & Kang, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01802-3 · Cited by 1
“Loss-of-function mutations in critical TCA cycle enzymes such as succinate dehydrogenase (SDH) and fumarate hydratase (FH) cause accumulation of succinate and fumarate, respectively 65 (Fig.”
Molecular clusters and precision medicine in pheochromocytomas and paragangliomas
Almeida, M. Q., Dahia, P. L. M., & Robledo, M. (2026) · Endocrine Related Cancer · doi:10.1530/erc-26-0258 · Cited by 1
Bai, Y., & Chen, W. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1931732 · Cited by 1
“Mutations in succinate dehydrogenase (SDH) and fumarate hydratase (FH) cause accumulation of succinate and fumarate, respectively, which inhibit a -ketoglutarate-dependent dioxygenases including prolyl hydroxylases that regulate HIF-1 a stability (Pollard et al., 2005; King et al., 2006).”
Metabolic Adaptation in Reprogrammed Cancer Cells
Marks, K. M., & Kung, C. K.-H. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9545-1_7 · Cited by 1
Mitochondrial Tumor Suppressors
Baysal, B. E. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_9 · Cited by 1
“Although overexpression of hypoxia-inducible genes was observed in HLRCC leiomyomas ( Pollard et al. 2005 ), but not in the sporadic leiomyomas, genome wide gene expression profiling in HLRCC leiomyomas indicates induction of glycolytic enzymes rather than hypoxia-inducible genes (Vanharanta et al. 2006).”
BackgroundHereditäre Paragangliome: Pathogenese und „Parent-of-Origin-Effekte“
Müller, U. (2010) · Medizinische Genetik · doi:10.1007/s11825-010-0240-1 · Cited by 1
The hypoxia-inducible factor (HIF) pathway in varicose veins
Lim, C. S. (2010) · doi:10.25560/6999 · Cited by 1
Dow, E., & Winship, I. (2018) · Familial Cancer · doi:10.1007/s10689-018-0081-7 · Cited by 1
Uchiumi, F., Arakawa, J., Takihara, Y., Akui, M., Hamada, H., & Tanuma, S. (2018) · InTech eBooks · doi:10.5772/intechopen.71095 · Cited by 1
“Several TCA cycles or metabolic enzymes functions as tumor suppressors [59, 64, 137], suggesting that mitochondrial dysfunction may lead to cancerous states.”
BackgroundChaves, K. F., Curlin, H. L., Harvey, L., Limperg, T. B., & Podoll, M. (2021) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000715 · Cited by 1
“FH is an enzyme in the tricarboxylic acid cycle that acts as a tumor suppressor [21].”
BackgroundAdnan, A., Raju, S., Kumar, R., & Basu, S. K. (2022) · PET Clinics · doi:10.1016/j.cpet.2022.03.010 · Cited by 1
The emerging genetic landscape of renal cell carcinoma
Lee, G., Shinder, B. M., Sadimin, E. T., Stephenson, R. D., & Singer, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822824-1.00035-3 · Cited by 1
Relevance of Mitochondrial Functions and Plasticity in Tumor Biology
Obre, É., Bellancé, N., José, C., Bénard, G., Nouette‐Gaulain, K., & Rossignol, R. (2014) · Springer eBooks · doi:10.1007/978-94-017-8984-4_11 · Cited by 1
MED12: A NOVEL PLAYER IN UTERINE LEIOMYOMAS
Mäkinen, N. (2015) · Helda - University of Helsinki Institutional Repository · Cited by 1
DEFECTS IN TRICARBOXYLIC ACID CYCLE ENZYMES FUMARATE HYDRATASE AND SUCCINATE DEHYDROGENASE IN CANCER
Ylisaukko‐oja, S. K. (2007) · Helda - University of Helsinki Institutional Repository · Cited by 1
The Pathogenesis of Pheochromocytomas: Of Mice and Men
Korpershoek, E. (2011) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 1
The role of Mcl-1 in the response of human colorectal cancer cells to treatment with dichloroacetate
Delaney, L. M. (2013) · The Atrium (University of Guelph) · Cited by 1
The role of MED12 in tumorigenesis
Kämpjärvi, K. (2016) · Helda - University of Helsinki Institutional Repository · Cited by 1
ON THE REPROGRAMMING OF THE KREBS CYCLE IN HYPOXIC AND VHL-DEFICIENT CANCER CELLS
Gameiro, P. A. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Ceramide synthase 4 : a novel metabolic regulator of oncogene-induced senescence
Dix, F. L. (2018) · ERA · Cited by 1
Role of microenvironment on neuroblastoma SK-N-AS SDHB silenced cell metabolism and function
Rapizzi, E., Fucci, R., Giannoni, E., Canu, L., Richter, S., Cirri, P., & Mannelli, M. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.37.oc8.2 · Cited by 1
“…as expected from the finding that succinate accumulation inhibits prolyl-hydroxylase activity and reduces HIF degradation (Dahia et al. 2005, Pollard et al. 2005, Selak et al. 2005, Koivunen et al. 2007, Favier et al. 2009, and, for recent reviews, see Richter et al. (2013) and Jochmanová…”
BackgroundInvestigating the effect of hypoxia on the JmjC histone lysine demethylase KDM4A
Hancock, R. L. (2016) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-yxq7r1a6r · Cited by 1
Wirthner, R. (2008) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-163745 · Cited by 1
Silas, Y., Singer, E., Das, K., Lehming, N., & Pines, O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.04.232652 · Cited by 1
“methlycytosine (5mC) hydroxylases [10, 17, 20, 23-26].”
Loriot, C. (2014) · theses.fr (ABES) · doi:10.70675/0070fd18z12e7z46e3za7a9z28581339b50e · Cited by 1
An investigation of the effect of some stable nitroxide antioxidants in prostate cancer cells
Eng, G. T. A. (2015) · QUT ePrints (Queensland University of Technology) · Cited by 1
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.